Home / Artifacts / TauRx Pharmaceuticals

📖

TauRx Pharmaceuticals

active

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-taurx-pharmaceuticals

Related Entities

companies-taurx-pharmaceuticals

Metadata

slug	companies-taurx-pharmaceuticals
kg_node_id	None
entity_type	company

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (54)

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%

related🧫Metabolic Pathway-Targeted Therapy in ALS60%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%

related🧫PSP and CBS Biomarker Validation Study60%

related🧫Brainstem Circuit Modulation for PSP60%

related🧫TDP-43 PET Ligand Development for FTD and ALS60%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%

related🧫N-of-1 Clinical Trial Design for CBS/PSP60%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%

related🧫Progranulin Replacement Therapy for FTD — Vector Development60%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%

related🧫Brainstem Circuit Modulation for PSP54%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%

related🧫Metabolic Pathway-Targeted Therapy in ALS54%

related🧫PSP and CBS Biomarker Validation Study54%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%

related🧫Progranulin Replacement Therapy for FTD — Vector Development54%

related🧫N-of-1 Clinical Trial Design for CBS/PSP54%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri54%

related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%

related🧫TDP-43 PET Ligand Development for FTD and ALS54%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🧪LRP1-Dependent Tau Uptake Disruption40%

related🧪TREM2-mediated microglial tau clearance enhancement40%

mentions📖Tau Protein40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

mentions📖Frontotemporal Dementia40%

mentions📖Alzheimer's Disease40%

💬 Discussion

Loading comments...